Anti-hyperalgesic effects of calcitonin on neuropathic pain interacting with its peripheral receptors.
BACKGROUND
The polypeptide hormone calcitonin is clinically well known for its ability to relieve neuropathic pain such as spinal canal stenosis, diabetic neuropathy and complex regional pain syndrome. Mechanisms for its analgesic effect, however, remain unclear. Here we investigated the mechanism of anti-hyperalgesic action of calcitonin in a neuropathic pain model in rats.


RESULTS
Subcutaneous injection of elcatonin, a synthetic derivative of eel calcitonin, relieved hyperalgesia induced by chronic constriction injury (CCI). Real-time reverse transcriptase-polymerase chain reaction analysis revealed that the CCI provoked the upregulation of tetrodotoxin (TTX)-sensitive Nav.1.3 mRNA and downregulation of TTX-resistant Nav1.8 and Nav1.9 mRNA on the ipsilateral dorsal root ganglion (DRG), which would consequently increase the excitability of peripheral nerves. These changes were reversed by elcatonin. In addition, the gene expression of the calcitonin receptor and binding site of 125I-calcitonin was increased at the constricted peripheral nerve tissue but not at the DRG. The anti-hyperalgesic effect and normalization of sodium channel mRNA by elcatonin was parallel to the change of the calcitonin receptor expression. Elcatonin, however, did not affect the sensitivity of nociception or gene expression of sodium channel, while it suppressed calcitonin receptor mRNA under normal conditions.


CONCLUSIONS
These results suggest that the anti-hyperalgesic action of calcitonin on CCI rats could be attributable to the normalization of the sodium channel expression, which might be exerted by an unknown signal produced at the peripheral nerve tissue but not by DRG neurons through the activation of the calcitonin receptor. Calcitonin signals were silent in the normal condition and nerve injury may be one of triggers for conversion of a silent to an active signal.
Laboratory for Development Pharmacology, Pharmaceuticals Research Center, Asahi Kasei Pharma Co. Ltd, 632-1 Mifuku, Izunokuni-shi, Shizuoka 410-2321, Japan. ito.ab@om.asahi-kasei.co.jp
Akitoshi
A
Ito
Mineko
M
Takeda
Takeshi
T
Yoshimura
Takayuki
T
Komatsu
Takeshi
T
Ohno
Hiroshi
H
Kuriyama
Akio
A
Matsuda
Megumu
M
Yoshimura
D000818:Animals; D002116:Calcitonin / Q000031:analogs & derivatives / Q000627:therapeutic use*; D005727:Ganglia, Spinal / Q000187:drug effects / Q000378:metabolism; D006930:Hyperalgesia / Q000188:drug therapy* / Q000378:metabolism*; D008297:Male; D009437:Neuralgia / Q000188:drug therapy* / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D060888:Real-Time Polymerase Chain Reaction; D018003:Receptors, Calcitonin / Q000235:genetics / Q000378:metabolism*; D015222:Sodium Channels / Q000378:metabolism
D018003:Receptors, Calcitonin; D015222:Sodium Channels; D002116:Calcitonin; C012755:elcatonin